Banshidhar Pharma capabilities include non-infringing synthetic route selection with respect to patents, processes and analytical validation, optimization and successful scale-up from bench to manufacturing. Production is undertaken in the state-of-the-art multi-purpose FDCA compliant manufacturing facility. In order to meet the regulatory requirements, molecule formation, isolation of API and their subsequent operations such as drying, milling, blending and packing are carried out in a facility having FDCA practices.

We offer 5 ready API's regulatory across Diuretics, Anti-Hypertensive, CNS, Cardiovascular, Anti-diabetic segments with product which are now generic API's We also have 5 molecules in the pipeline.

We offer 2 ready Advances Intermediates regulatory across Diuretics, Anti-Hypertensive, CNS, Cardiovascular, Anti-diabetic segments with product which are now generic Advances Intermediates. We also have 3 molecules in the pipeline.